$HWKN

Hawkins, Inc. (NASDAQ:HWKN) Receives Average Recommendation of "Moderate Buy" from Brokerages

Hawkins, Inc. (NASDAQ:HWKN) has received an average rating of "Moderate Buy" from five brokerages, with three assigning a buy rating and two a hold rating. The average 12-month price target for HWKN is $162.50. Despite missing recent quarterly earnings and revenue estimates, the company's stock trades near $157.66, with significant institutional ownership and recent insider buying activity.

Original reporting
MarketBeat · MarketBeat
Published Jan 12, 2026, 4:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jan 12, 2026, 4:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hawkins, Inc. (NASDAQ:HWKN) Receives Average Recommendation of "Moderate Buy" from Brokerages — source image
Decision brief

The 30-second read

$HWKNNeutralLow
01

Why it matters

The mixed earnings and positive analyst sentiment create a cautiously optimistic environment, with potential for moderate stock appreciation.

02

Market read

The news is relevant for investors holding or considering Hawkins, Inc. stock, especially those focused on mid-cap industrial companies.

03

What to watch

Potential upcoming catalysts such as new product launches or strategic initiatives could alter the outlook positively.

Timing: Long-term

Background

Hawkins, Inc. has experienced recent earnings misses but maintains a moderate buy consensus among analysts, supported by insider buying and institutional ownership.

Company-level read

Ticker impact

$HWKNNeutralMedium confidence
Context

The news pertains directly to Hawkins, Inc., a NASDAQ-listed company, and provides a comprehensive overview of analyst ratings and market sentiment.

Expected impact

Potential slight upward movement towards the target price of $162.50 over the next 12 months.

Evidence & confidence

The mixed earnings report introduces some caution, but positive analyst ratings and insider activity support a cautiously optimistic outlook.

$HWKNNeutralMedium confidence
Context

The sentiment score indicates a neutral market perception, aligning with the 'Moderate Buy' rating and mixed recent earnings performance.

Expected impact

Possible gradual increase towards the target price, with limited short-term volatility expected.

Evidence & confidence

Market sentiment is balanced, with no strong bullish or bearish signals, implying a stable outlook.

Market effects

The company's performance and analyst sentiment may influence related industrial and manufacturing sectors.

Limited regional impact; primarily relevant to investors and stakeholders in the company's geographic and industry markets.

Minimal; the news is specific to Hawkins, Inc. and does not significantly affect global markets.

Counterpoint

Some analysts may interpret the earnings miss as a sign of underlying issues, suggesting caution against over-optimism.

Key entities

  • Hawkins, Inc.

    A provider of specialty chemicals and ingredients.

Related articles

$HWKNMed

HAWKINS INC (HWKN): Results of Operations and Financial Condition

HAWKINS INC (HWKN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hwknex9912027-q1.htm EX-99.1 Document Exhibit 99.1 Hawkins, Inc. Reports First Quarter Fiscal 2027 Results Roseville, Minn., July 29, 2026 – Hawkins, Inc. (Nasdaq: HWKN) today announced results for the three months ended June 28, 2026, its first quarter of fiscal 2027.

$HNGEMed

Jim Cramer says one stock hitting new highs is still a screaming buy

Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.

$NVDAMed

Nvidia scales back funding guarantee for Ohio OpenAI data center, WSJ reports

Reuters, citing the WSJ, says Nvidia scaled back its funding guarantee for a proposed OpenAI data center in Ohio. Nvidia is expected to initially guarantee less than $120 billion versus $250 billion previously discussed, covering only the first phase. A deal could be signed as soon as this weekend. OpenAI and Nvidia are nearing agreement; SB Energy (SoftBank unit) would develop the 10 GW site.

$METAMed

TerraPower Signs Hyundai as EPC for Eight Natrium Reactors

TerraPower said it selected Hyundai Engineering and Construction as EPC for up to eight 345 MW Natrium reactor and energy storage plants, with Meta funding and initial deliveries as early as 2032. TerraPower also signed a term sheet with SK Innovation to pursue Korea’s first commercial Natrium plant. Separately, the DOE plans to award X-energy $1B for four 80 MW HTGRs at Dow’s Texas site.

$FLYMedAI 8/10

SciTec wins $94M Space Force contract – BizWest

SciTec, a subsidiary of Firefly Aerospace (Nasdaq: FLY), won a nearly $94 million U.S. Space Force contract to supply ground-based radar digitization for Space Systems Command in Colorado Springs. SciTec said the work will modernize radars via a common architecture and design. SciTec was absorbed into Firefly last year for $855 million.